FTDI
ALNY icon

First Trust Direct Indexing’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Trust Direct Indexing’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,895
Closed -$521K – 41
2024
Q3 		$521K Sell
1,895
-1,047
-36% -$273K 0.03% 533
2024
Q2 		$715K Buy
2,942
+286
+11% +$45.2K 0.04% 408
2024
Q1 		$397K Sell
2,656
-242
-8% -$40.4K 0.03% 537
2023
Q4 		$555K Buy
2,898
+340
+13% +$57.9K 0.05% 418
2023
Q3 		$453K Buy
2,558
+187
+8% +$35.7K 0.05% 421
2023
Q2 		$450K Buy
2,371
+84
+4% +$16.7K 0.05% 439
2023
Q1 		$458K Sell
2,287
-183
-7% -$38.5K 0.05% 429
2022
Q4 		$587K Buy
2,470
+271
+12% +$57.8K 0.08% 334
2022
Q3 		$440K Sell
2,199
-181
-8% -$34.5K 0.06% 374
2022
Q2 		$347K Sell
2,380
-517
-18% -$73.3K 0.05% 431
2022
Q1 		$473K Buy
2,897
+710
+32% +$108K 0.06% 385
2021
Q4 		$371K Buy
2,187
+87
+4% +$16.2K 0.05% 438
2021
Q3 		$397K Buy
2,100
+159
+8% +$29.8K 0.06% 401
2021
Q2 		$329K Sell
1,941
-190
-9% -$27.8K 0.05% 441
2021
Q1 		$301K Hold
2,131
– – 0.08% 310
2020
Q4 		$277K Buy
+2,131
New +$285K 0.07% 299

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

First Trust Direct Indexing's ALNY Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 1,895 shares — an estimated $521K sold.

First Trust Direct Indexing first reported a position in ALNY in Q4 2020 and held it in 16 quarters. The position peaked at $715K in Q2 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • First Trust Direct Indexing reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • First Trust Direct Indexing sold 1,895 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $521K.
  • First Trust Direct Indexing first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • First Trust Direct Indexing's Alnylam Pharmaceuticals position peaked at $715K in Q2 2024.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.